3Osendarp SJ, van Raaij JM, Darmstadt GL, et al. Zinc supplementation during pregnancy and effects on growth and morbidity in low birthweight infants: a randomised placebo controlled trial. Lancet, 2001,357:1080 - 1085.
4Capoluongo E, Giglio A, Belardi M, et al. Association between lesional or non lesional S. aureus strains from patients with impetigo and exfoliative toxin production. No association with SmaI PFGE patterns.New Microbiol, 2000, 23:21 - 27.
5Halns CS, Johnson SE, Nelson KG. Once daily cefadroxil therapy for pyoderma. Pediatr Infect Dis J, 1989, 8:648 -649.
6Ardiles L, Ramirez P, Moya P, et al. Antieardiolipin antibodies in acute poststreptococcal glomerulonephritis and streptococcal impetigo.Nephron, 1999, 83:47 - 52.
7Nishijim S, Ohshima S, Higashida T, et al. Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000. Int J Dermatol, 2003, 42:23-25.
8Feder HM Jr, Abrahamian LM, Grant-Kels JM. Is penicillin still the drug of choice for non-bullous impetigo? Lancet, 1991, 338(8770):803 - 805.
9Amagai M, Yamaguchi T, Hanakawa Y, et al. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol,2002, 118:845 - 850.
10Oono T, Kanzaki H, Yoshioka T, et al. Staphylococcal scalded skin syndrome in an adult. Identification of exfoliative toxin A and B genes by polymerase chain reaction. Dermatology, 1997, 195:268 -270.
